A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients

Trial Profile

A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs L19-IL2 fusion protein (Primary) ; L19 TNF fusion protein
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 12 Oct 2017 According to a Philogen media release, the US FDA has approved an IND for this trial in USA.
    • 25 Oct 2016 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2018.
    • 21 Jan 2016 Status changed from planning to recruiting, according to a Philogen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top